Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 18 | 2024 | 73 | 9.540 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2024 | 296 | 2.910 |
Why?
|
| Bevacizumab | 9 | 2024 | 270 | 2.710 |
Why?
|
| Laser Coagulation | 7 | 2021 | 56 | 2.290 |
Why?
|
| Gestational Age | 12 | 2024 | 327 | 2.190 |
Why?
|
| Endophthalmitis | 2 | 2023 | 22 | 1.640 |
Why?
|
| Cataract Extraction | 2 | 2023 | 33 | 1.640 |
Why?
|
| Infant, Newborn | 20 | 2024 | 2506 | 1.630 |
Why?
|
| Cataract | 2 | 2023 | 87 | 1.150 |
Why?
|
| Infant, Premature | 8 | 2024 | 298 | 1.130 |
Why?
|
| Birth Weight | 2 | 2024 | 149 | 1.110 |
Why?
|
| Intravitreal Injections | 7 | 2024 | 80 | 1.030 |
Why?
|
| Infant | 11 | 2024 | 3205 | 0.920 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 63 | 0.890 |
Why?
|
| Infant, Premature, Diseases | 2 | 2021 | 75 | 0.860 |
Why?
|
| Neonatal Screening | 1 | 2024 | 65 | 0.850 |
Why?
|
| Aphakia | 1 | 2023 | 10 | 0.820 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2023 | 43 | 0.790 |
Why?
|
| Retrospective Studies | 13 | 2024 | 9679 | 0.770 |
Why?
|
| Lens, Crystalline | 1 | 2023 | 69 | 0.760 |
Why?
|
| Developmental Disabilities | 1 | 2023 | 201 | 0.750 |
Why?
|
| Hypertension | 2 | 2024 | 763 | 0.730 |
Why?
|
| Databases, Factual | 1 | 2023 | 955 | 0.630 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 556 | 0.600 |
Why?
|
| Myopia | 2 | 2017 | 12 | 0.560 |
Why?
|
| Humans | 36 | 2024 | 92303 | 0.530 |
Why?
|
| Postoperative Complications | 2 | 2023 | 2450 | 0.490 |
Why?
|
| Ophthalmology | 1 | 2016 | 46 | 0.480 |
Why?
|
| Uganda | 2 | 2024 | 41 | 0.450 |
Why?
|
| Risk Factors | 5 | 2024 | 5705 | 0.440 |
Why?
|
| Tomography, Optical Coherence | 7 | 2024 | 149 | 0.430 |
Why?
|
| Insurance, Health | 2 | 2024 | 172 | 0.400 |
Why?
|
| Choroid | 2 | 2024 | 36 | 0.400 |
Why?
|
| Communication | 1 | 2016 | 463 | 0.390 |
Why?
|
| Child | 7 | 2023 | 7303 | 0.390 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 411 | 0.380 |
Why?
|
| Male | 16 | 2024 | 43924 | 0.370 |
Why?
|
| Female | 17 | 2024 | 47894 | 0.370 |
Why?
|
| Proteomics | 1 | 2023 | 246 | 0.360 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 630 | 0.350 |
Why?
|
| Retinal Detachment | 2 | 2021 | 68 | 0.340 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2023 | 410 | 0.320 |
Why?
|
| Child, Preschool | 3 | 2023 | 3803 | 0.320 |
Why?
|
| Physicians | 1 | 2016 | 693 | 0.300 |
Why?
|
| Incidence | 2 | 2023 | 1661 | 0.300 |
Why?
|
| Retinal Vessels | 3 | 2024 | 59 | 0.290 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 1920 | 0.290 |
Why?
|
| Fluorescein Angiography | 4 | 2023 | 104 | 0.280 |
Why?
|
| Scleritis | 1 | 2016 | 6 | 0.270 |
Why?
|
| Sclera | 1 | 2016 | 13 | 0.270 |
Why?
|
| Founder Effect | 1 | 2017 | 105 | 0.260 |
Why?
|
| Streptococcal Infections | 1 | 2016 | 55 | 0.260 |
Why?
|
| Internship and Residency | 1 | 2016 | 1083 | 0.260 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2024 | 13 | 0.230 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2024 | 64 | 0.220 |
Why?
|
| Retinal Perforations | 1 | 2024 | 19 | 0.220 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2024 | 75 | 0.210 |
Why?
|
| Diabetic Retinopathy | 1 | 2024 | 92 | 0.200 |
Why?
|
| Parturition | 1 | 2022 | 23 | 0.200 |
Why?
|
| Mobile Applications | 1 | 2024 | 76 | 0.200 |
Why?
|
| Smartphone | 1 | 2023 | 45 | 0.200 |
Why?
|
| Child Development | 1 | 2024 | 168 | 0.190 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2021 | 8 | 0.190 |
Why?
|
| Fovea Centralis | 1 | 2021 | 21 | 0.190 |
Why?
|
| Feasibility Studies | 1 | 2024 | 800 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3773 | 0.180 |
Why?
|
| United States | 2 | 2024 | 7346 | 0.180 |
Why?
|
| Mucolipidoses | 1 | 2021 | 3 | 0.180 |
Why?
|
| Connective Tissue Diseases | 1 | 2021 | 70 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 356 | 0.170 |
Why?
|
| Movement | 1 | 2022 | 318 | 0.170 |
Why?
|
| Oxygen | 1 | 2024 | 763 | 0.160 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.160 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 9 | 0.160 |
Why?
|
| Refraction, Ocular | 1 | 2019 | 11 | 0.160 |
Why?
|
| Vitreous Hemorrhage | 1 | 2018 | 12 | 0.150 |
Why?
|
| Hearing Loss | 1 | 2019 | 63 | 0.150 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 98 | 0.150 |
Why?
|
| Vitreous Body | 1 | 2018 | 57 | 0.150 |
Why?
|
| Keratoconus | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 1775 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1073 | 0.140 |
Why?
|
| Cornea | 1 | 2017 | 71 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2019 | 694 | 0.140 |
Why?
|
| Adolescent | 3 | 2023 | 9491 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2024 | 8727 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 760 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2024 | 4469 | 0.110 |
Why?
|
| Aqueous Humor | 1 | 2023 | 26 | 0.100 |
Why?
|
| Syndrome | 2 | 2021 | 449 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 198 | 0.100 |
Why?
|
| Video Recording | 2 | 2024 | 204 | 0.090 |
Why?
|
| Fundus Oculi | 2 | 2023 | 37 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 807 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2023 | 466 | 0.080 |
Why?
|
| Time Factors | 1 | 2019 | 5430 | 0.080 |
Why?
|
| Adult | 5 | 2023 | 27535 | 0.080 |
Why?
|
| Fluoresceins | 1 | 2018 | 45 | 0.080 |
Why?
|
| Axial Length, Eye | 1 | 2017 | 2 | 0.070 |
Why?
|
| Retinoscopy | 1 | 2017 | 2 | 0.070 |
Why?
|
| South Dakota | 1 | 2017 | 47 | 0.070 |
Why?
|
| Zinc | 1 | 2008 | 100 | 0.070 |
Why?
|
| Biometry | 1 | 2017 | 68 | 0.070 |
Why?
|
| Anterior Eye Segment | 1 | 2016 | 7 | 0.070 |
Why?
|
| Visual Acuity | 2 | 2018 | 221 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2008 | 142 | 0.070 |
Why?
|
| Biomarkers | 1 | 2023 | 1851 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 1 | 2008 | 441 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2008 | 260 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2008 | 684 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2008 | 282 | 0.060 |
Why?
|
| Ophthalmoscopy | 1 | 2024 | 14 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2016 | 707 | 0.050 |
Why?
|
| Vitrectomy | 1 | 2024 | 56 | 0.050 |
Why?
|
| Motor Skills | 1 | 2024 | 79 | 0.050 |
Why?
|
| Morbidity | 1 | 2023 | 157 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1594 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 808 | 0.050 |
Why?
|
| Retina | 1 | 2024 | 225 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 786 | 0.050 |
Why?
|
| Lasers | 1 | 2021 | 106 | 0.050 |
Why?
|
| Arthritis | 1 | 2021 | 49 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2021 | 48 | 0.050 |
Why?
|
| Capillaries | 1 | 2021 | 90 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 198 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 147 | 0.040 |
Why?
|
| Neuraminidase | 1 | 2021 | 47 | 0.040 |
Why?
|
| Parents | 1 | 2024 | 296 | 0.040 |
Why?
|
| Chicago | 1 | 2024 | 1466 | 0.040 |
Why?
|
| Young Adult | 2 | 2021 | 6628 | 0.040 |
Why?
|
| Corneal Topography | 1 | 2017 | 10 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 2793 | 0.040 |
Why?
|
| Aged | 2 | 2021 | 19952 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6916 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1960 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 3112 | 0.030 |
Why?
|
| Middle Aged | 2 | 2021 | 27043 | 0.030 |
Why?
|
| Oxacillin | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 2008 | 39 | 0.020 |
Why?
|
| Solutions | 1 | 2008 | 86 | 0.020 |
Why?
|
| Phospholipids | 1 | 2008 | 112 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 77 | 0.020 |
Why?
|
| Vancomycin | 1 | 2008 | 73 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2008 | 168 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 402 | 0.020 |
Why?
|
| Water | 1 | 2008 | 292 | 0.020 |
Why?
|